
Quarterly report 2022-Q2
added 08-15-2022
Gracell Biotechnologies EBITDA 2011-2026 | GRCL
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Gracell Biotechnologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -419 M | -207 M | -141 M | -59.5 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -59.5 M | -419 M | -207 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Graybug Vision
GRAY
|
-23.1 M | - | -11.23 % | $ 9.65 M | ||
|
Apellis Pharmaceuticals
APLS
|
57 M | $ 20.16 | -2.61 % | $ 2.54 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.79 | -6.17 % | $ 4.31 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 3.71 | -2.88 % | $ 1.11 B | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-49.5 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
-166 M | $ 164.05 | -1.4 % | $ 8.16 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-11.5 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 8.55 | -2.06 % | $ 1.39 B | ||
|
BridgeBio Pharma
BBIO
|
-518 M | $ 64.53 | -1.48 % | $ 12.4 B | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
-7.57 M | - | - | $ 789 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
BioMarin Pharmaceutical
BMRN
|
489 M | $ 58.53 | -2.03 % | $ 11.2 B | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-22.2 M | - | -16.75 % | $ 25.8 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Clovis Oncology
CLVS
|
-217 M | - | -7.23 % | $ 13 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
CTI BioPharma Corp.
CTIC
|
-77.8 M | - | - | $ 1.2 B | ||
|
CohBar
CWBR
|
-12.3 M | - | -15.44 % | $ 2.2 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-12 M | - | -5.98 % | $ 34.1 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-12 M | - | -4.36 % | $ 27 M | ||
|
Cabaletta Bio
CABA
|
-73.2 M | $ 3.25 | -1.52 % | $ 3.8 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-209 M | - | - | $ 2.18 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Capricor Therapeutics
CAPR
|
-23 M | $ 25.84 | -3.8 % | $ 692 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Codexis
CDXS
|
-53.6 M | $ 0.98 | -3.92 % | $ 71.9 M | ||
|
Certara
CERT
|
96.2 M | $ 7.24 | 2.7 % | $ 1.16 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Entasis Therapeutics Holdings
ETTX
|
-52.2 M | - | - | $ 105 M | ||
|
Evofem Biosciences
EVFM
|
-17.4 M | - | 7.55 % | $ 38.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Coherus BioSciences
CHRS
|
-200 M | $ 1.65 | - | $ 155 M | ||
|
Evelo Biosciences
EVLO
|
-106 M | - | -14.46 % | $ 27.9 M |